Corporate Brochure IBA 2010 by Plasticine

ď&#x192;&#x192;

IBA Locations & Contacts: see previous pages.

IBA â&#x20AC;&#x201C; Protect enhance and save lives

IBA Corporate brochure v1 - November 2010

IBA delivers solutions of unprecedented precision in the fields of cancer diagnosis and therapy. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life.

personalized care

for all

Developing concrete innovative solutions to make medicine more personalized, more efficient and more accessible.

BIOASSAYS // MOLECULAR IMAGING // PARTICLE THERAPY // DOSIMETRY // INDUSTRY SOLUTIONS

I BA: Cutting a long story short and table of contents.

1986

2001

Founding of IBA (Ion Beam Applications):

IBA develops its presence in the

development of cyclotrons for the production of

radiopharmaceutical sector:

isotopes for Medical Imaging

Acquisition of Eastern Isotopes

1992

First patient treated in an IBA clinical Proton

IBA expands its activities into Sterilization and

Therapy center at MGH

Ionization

1997 Employees’ Buy Out

1998 IBA enters the Brussels Stock Market

1998/1999

Over

Worldwide presence years of Innovation

2006 For its 20th birthday IBA focuses its strategy on fighting Cancer and grants itself a new brand identity

2007 Developing presence in Asia

Headquarters

Radiopharmaceuticals production

IBA enters the field of Dosimetry through the

2006/2008

acquisition of Scanditronix and Wellhöfer

IBA develops its presence in Europe

Main offices

for the production and distribution of

IBA Asia-Pacific

Beijing

radiopharmaceuticals: acquisition of the

IBA Industrial

Louvain-la-Neuve

IBA consolidates its strength in irradiation

Schering radiopharmaceutical business and CIS

IBA Industrial

Edgewood, NY

technologies by the acquisition of Radiation

bio International

IBA Molecular

Saclay

IBA Molecular

Sterling, VA

IBA Dosimetry

Schwarzenbruck

IBA Dosimetry

Bartlett, TN

IBA Particle Therapy

Louvain-la-Neuve

IBA Particle Therapy

Jacksonville, FL

CISBIO Bioassays

Bagnols-sur-Cèze

1999 Dynamics, Inc

IBA Group

Louvain-la-Neuve

Belgium

and distribution sites northern america

China

pet sites

Belgium USA France

Europe

cGMP pet sites

USA Germany USA

asia

cGMP pet sites

Belgium USA France

iba locations & contacts. // 44

ABOUT IBA Protect, enhance and save lives IBA. Making cancer treatment more efficient at a lower cost for society. Personalized care for all. IBA. Deeply ingrained values... IBA. Integrated activities...

03 04 06 08

Bioassays Shaping medicine with innovative assays Improving human healthcare by providing high quality biological solutions.

Molecular Imaging giving ideas a future IBA. Making personalized diagnostic a reality. IBA. Developing the next generation radiopharmaceuticals. IBA. Delivering service and quality, every day. IBA. A global integrated solution for radioisotopes production.

16 18 20 22

PARTICLE THERAPY today, more than ever... IBA. Making particle therapy available to more patients, everywhere, everyday. IBA. Where vision becomes reality. IBA. Where experience really matters. IBA. Proton therapy made accessible at lower costs and smaller size.

26 28 30 32

Dosimetry Fastest, most accurate, most reliable IBA. Enabling safer radiation in medical diagnostics and treatment. 34

Industry Solutions Act responsibly IBA. Leadership in E-Beam accelerators to improve your industrial processes. The cleanest and most environment-friendly solutions on the market.

protect, enhance and

s â&#x20AC;&#x2030; ave lives

2 // iba ABOUT IBA

IBA. Making cancer treatment more efficient at a lower cost for society. The rise of healthcare costs and the growing number of cancer patients worldwide represent one of the biggest challenges our society will have to face in theÂ comingÂ decades. At IBA, we are committed to developing leading-edge technologies and concrete innovative solutions to make medicine more personalized, more efficient and more accessible for the patient while in the long run, more cost-effective for society. Every day, by making personalized treatments a reality for all, we support physicians worldwide to Protect, Enhance and Save Lives. Pierre Mottet, CEO.

iba ABOUT IBA // 3

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

Personalized care for all.

Triumphing over illness and recovering

patient care and, in the long run, to

tice for the diagnosis of their patients

full health is the wish of every patient,

more cost-effective healthcare for the

as well as for treatment response

the goal of each physician and the

benefit of patients and society.

evaluation.

motivation for all researchers.

Our Commitment at IBA, …

In oncology for example, the use of

Yet, today, with an aging popula-

Thus, at IBA, we are committed to de-

specific PET imaging can, in one case

tion and the funding of healthcare

veloping leading-edge technologies

out of three, enable the physician to

evermore challenging, the “one size

and concrete innovative solutions to

adapt the treatment procedure just a

fits all” approach must unavoidably

make medicine more specific, more

few days after it has started.

be questioned. It is a fact that in add

efficient and more accessible for

 Making specific treatment that

ition to technological limits, the lack

the patient while more cost-effective

avoids side effects more accessible

of precision in diagnostics and treat-

for society.

In combination with this unique im-

ment procedures leads to high levels

aging technique, IBA is committed

of treatment inefficiency. Inevitably, the

Every day, we support physicians

to making precise treatment access

healthcare budget and cost to society

worldwide to make personalized care

ible to more patients worldwide. IBA

are negatively impacted.

a reality for all. We do so by taking

develops innovative proton therapy

2 main integrated paths:

technologies associated with high

Towards a solution

 Improving the precision of diagno-

end dosimetry solutions. These allow

At IBA, we believe that a more precise

sis and treatment response evaluation

the physician to deliver with certainty

diagnosis using functional images (i.e.

thanks to Molecular Imaging

high radiation doses to very precise

PET and SPECT ) will enable a more

IBA provides its partners with a unique

locations in the body. By confining the

specific treatment, such as proton

combination of know-how and innova-

dose to the tumor, IBA proton therapy

therapy, and a faster assessment of

tion capabilities in PET Radiopharma-

proposes a treatment method that

treatment response.

ceutical development combined with a

reduces side effects drastically while

global distribution network. It enables

diminishing the probability of second-

This more individualized approach to

physicians to use specific functional

ary cancers.

patient treatment will lead to improved

imaging as part of their daily prac-

4 // iba ABOUT IBA

Every effort we make, every action we take is a new step towards a more PERSONALIZED approach to patient treatment.

By providing patients with a more efficient treatment with fewer side effects and lower risk of relapse, this unique approach directly benefits patients worldwide while lowering the longterm cost of healthcare to society. At IBA, we work relentlessly with our customers to explore new horizons in medical fields and the industrial world to Protect, Enhance and Save Lives. (1) Positron Emission Tomography (2) Single Photon Emission Tomography

Today’s treatment efficacy

25% 30% 57%

“ Through the early identification and initiation of optimal treatments, personalized medicine has the potential

Cancer,

to lower the overall cost of healthcare dramatically.” Harvard Business Review, October 2007

Estimation based on: Brian B Spear, “Clinical Application of Pharmacogenetics”, Trends in Molecular Medicine, May 2001

iba ABOUT IBA // 5

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Deeply ingrained values, a compelling mission.

IBA was created by people who are

Through challenges and an attitude

committed to developing technology

of fairness, we stimulate excellence

Making Business success sustainable

to fight cancer. As the company grew,

amongst all IBA employees and make

To achieve sustainable business

this passion evolved naturally into

our business an exciting experience.

success

deeply ingrained beliefs that govern

The outcome is the creation of tang

the areas of health, safety and

our business behavior.

ible value for patients, our customers

the environment, IBA is engaged

and shareholders.

in,

Why do we fight?

through

amongst

excellence

others,

two

main

programs:

Everyone is concerned by cancer and

“ I know of no other company that

1. I BA is engaged in a voluntary

other major diseases. IBA employees

would have the courage to open it-

agreement with the European

share a feeling of urgency in this mat-

self up to its customers the way IBA

Commission to reduce and op-

ter and are inspired by the mission to

does at its user meetings. This in turn

timize energy consumption and

Protect, Enhance and Save Lives.

engenders a high degree of loyalty

implement EcoDesign methods

from users such as myself who prize

to reduce energy consumption

What do we think?

information access above everything.

throughout our equipment’s life

We achieve our business goals be-

This is one of the reasons why I rec-

cycle.

cause we dare to create innovative

ommend IBA’s products.”

and superior science to detect and treat cancer. We share knowledge, experience and expertise with our

Prof. Roger Price, Head, Medical Technology, Physics & Radiopharmaceutical Production & Development, Sir Charles Gairdner Hospital, Perth, Australia. (Cyclone® 18/9 since 2003)

customers and partners, listening carefully to their needs, understanding their requirements. This dialogue enables us to provide them with operational solutions and concrete results that improve patient lives, which is what we care about.

6 // iba ABOUT IBA

More information on www.iba-worldwide.com

2. I BA is committed to ensuring safety at work for all employees by raising and aligning standards of safety throughout the Group.

At IBA, people are inspired by a common mission: to Protect, Enhance and Save Lives.

iba ABOUT IBA // 7

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Integrated activities to realize accessible personalized care for all.

What do we do?

R&D and partnerships and by com-

and safety in diagnostics and therapy

Our complementary solutions in

bining its capacity to develop new

through accurate dosimetry.

pharmaceuticals and medical equip-

radiopharmaceuticals within a wide

Extending its expertise in particle

ment improve disease diagnosis

distribution network with the largest

acceleration related technologies to

and therapy today, and promise even

product portfolio in the market, and

industrial sectors, IBA develops and

more effective treatment tomorrow.

its expertise in radiochemistry and

supplies industry with surprising and

particle acceleration.

environment-friendly sterilization and

IBA applies its unique know-how and

ionization processes for everyday life.

innovation capabilities to healthcare.

Through countless efforts in R&D, in-

Every day, the IBA team works to make

telligent partnerships and the com-

personalized care real and accessible

mitment of all those involved, IBA

to more patients.

is continuously developing particle therapy solutions for patient care.

By offering superior specificity and

These solutions will help control and

sensitivity to diagnostics, IBA mo-

cure cancer worldwide in the most

lecular imaging is opening up new

flexible, effective and empathetic way

opportunities in the early detection,

possible. Having pioneered the field

characterization and evaluation of

of particle therapy and become the

treatment response. This field gives

worldwide leader in this market, IBA

healthcare new solutions on the path

is committed to following this path and

towards a more personalized and ef-

offering its customers ever more flex-

fective medicine.

ible and accessible state-of-the-art particle therapy solutions.

To give those ideas a future, IBA has adopted a unique position and is com-

In addition to these core activities,

mitted to become a major player in

IBA has the firm intention to develop

this new era of radiopharmaceuticals.

all its fields of expertise. This includes,

The company will achieve this through

for example, enhancing the precision

8 // iba ABOUT IBA

Bioassays // molecular imaging // particle therapy // dosimetry // industrial applications

iba ABOUT IBA // 9

Cisbio Bioassays

Shaping medicine with innovative

assays Cisbio Bioassays strives to enhance patient care through assays that enable uncompromised patient diagnosis and deliver solutions for the investigation and discovery of tomorrow’s new drugs.

10 // iba BIOASSAYS

iba BIOASSAYS // 11

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

Improving human healthcare by providing high quality biological solutions. What are Bioassays?

To do so, Cisbio develops, manufac-

as immunoassay design. While offering

Bioassays are a paramount element

tures and markets diagnostic assays

a catalogue of more than 80 products,

of life sciences. They consist of a

for the quantification of tumor markers

Cisbio clearly focuses on oncology with

large set of methods and tools used

and other biomarkers in clinical biol-

more than 50% of its references being

to analyse and quantify biological

ogy, providing the medical community

tumor markers. As such, Cisbio plays a

molecules in samples, particularly in

with reliable and sensitive diagnos-

central role in the diagnosis and prog-

an in vitro context. When developed

tic tools.

nosis of patients suffering from cancer.

as immunoassays for in vitro diag-

Cisbio Bioassays enables pharma-

nostics, these processes must allow

ceutical and biotechnology compa-

a highly reliable measurement of

nies, contract research organizations

In Vitro Diagnostics Markers - A standard in the industry

biomarkers in human blood and tis-

(CROs) and academic institutes to

Cisbio’s in vitro diagnostics products

sues to help patient disease diagno-

shape the drugs of tomorrow.

are renowned worldwide for their quality and robustness, so much so that

sis and follow-up. In drug discovery,

Cisbio products are used as refer-

can be optimized to investigate the

Pioneering new markers, focusing on oncology

biology and pharmacology of thera-

Improving the precision of diagnostics

of scientists is dedicated to ensur-

peutic targets among which the in-

will enable physicians to provide spe-

ing strict quality assurance and that

dustry and the academic field are

cific and adapted treatment. Hence,

Cisbio’s very high standards are met,

seeking new drug candidates.

this individualized approach of treat-

consistently. Cisbio has ISO 9001 and

ment allows a better patient care at

ISO 13485 certification for all its in vitro

Biomedical technologies for biomarker assessment and drug screening

lower societal costs.

diagnostics products.

Cisbio Bioassays explores biology and

ing track record in the development of

immunoassay design to provide physi-

novel immunoassays, based on more

cians, biologists, clinical chemists and

than two decades of experience in the

scientists with enhanced solutions for

production and optimization of mono-

improving patient care.

clonal and polyclonal antibodies as well

very similar experimental settings

12 // iba BIOASSAYS

ences throughout the industry. A team

Cisbio’s R&D teams have an outstand-

The development of an immunoassay for Chromogranin A, marked a milestone in clinical biology for the follow up of neuroendocrine tumors

HTRF for advanced Drug Discovery

Dedicated to customer results

Key player in the GPCR market

Cisbio has always been at the forefront

Cisbio is renowned across the world

Through its product offering, Cisbio

of innovation, applying novel technolo-

for its dedication to meeting customer

addresses most of the therapeutic

gies and assays to the drug discovery

needs and for its custom services pro-

targets explored in modern drug

process. Its proprietary technology,

gram. Beyond selling state-of-the-art

discovery, such as oncology-relat-

HTRF , based on research by a Nobel

products, Cisbio endeavors to provide

ed kinase enzymes, or inflammation

Prize winner, uses advanced fluores-

hands-on technical support, recog-

and metabolic disease biomarkers.

cence chemistry to identify interactions

nized by key industry players as sec-

Among these targets, G-protein

between complex biological entities.

ond-to-none.

coupled receptors (GPCRs), which

This robust and integrated technology

From assisting a customer in imple-

are present in every organ system,

platform provides critical benefits to

menting an HTRF assay, to developing

have been validated as therapeutic

drug discovery customers, contributing

a custom assay to meet very specific

targets in areas including central

to streamline their research processes

needs, Cisbio’s team of scientific con-

nervous system disorders, car-

and screening, and helping them to

sultants is highly involved in all aspects

diac dysfunction, pain, inflamma-

find tomorrow’s therapies.

of customer service and support, and

tion, cancer, diabetes, and obesity.

is truly committed to helping its custom-

Drugs targeting GPCRs account

ers reach their research goals.

for the majority of the best selling

drugs and about 40% of all preMore information on in vitro diagnostics www.ria-cis.com or Drug Discovery www.htrf.com

scription pharmaceuticals in the marketplace. Cisbio is committed to developing new tools to further explore GPCRs’ function and mechanism of action, through novel approaches to the study of these targets under a cellular, close-to-

Cisbio Bioassays employs the most advanced technologies and equipment to meet pharmaceutical industry demands

physiology environment.

iba BIOASSAYS // 13

IBA Molecular Imaging

â&#x20AC;&#x2030;Giving Ideas a

Future Molecular Imaging allows to easily diagnose,treat and stage disease. Thanks to itâ&#x20AC;&#x2122;s unique capabilities in Molecular Imaging, IBA will enable personalized medicine, therefore bringing major benefits to both patients and healthcare systems.

14 // iba MOLECULAR IMAGING

iba MOLECULAR IMAGING // 15

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Making personalized diagnostic a reality.

What is Molecular Imaging?

IBA Molecular is part of this progress.

aging is an in vivo imaging tech-

Radiopharmaceutical development, production and distribution Towards personalized medicine

nique that enables the non-invasive

IBA believes that the use of molecular

healthcare centers around the world.

visualization of cellular function and

medicine in everyday healthcare prac-

tracking of the molecular process

tice is still in its infancy. We share the

By providing superior science and ser-

in living organisms. Biomarkers

enormous enthusiasm of the world-

vice in both production and distribution,

or tracers are used to help image

wide medical community for the de-

we are helping to ensure the uninter-

particular targets or pathways. The

velopment of more personalized and

rupted supply of radiopharmaceuticals

ability to image small molecular

effective medicine through accurate

that is vital for the highest standards of

changes opens up a number of

molecular diagnosis. Building for this

patient care.

possibilities for medical applica-

future, IBA Molecular has established

tions, including earlier detection,

strategic partnerships with research

more accurate diagnosis and im-

institutions and biotechnology com-

Comprehensive range of nuclear medicine solutions

proved treatment monitoring. Mo-

panies

new-generation

Fulfilling our role as the leader in radio-

lecular imaging will also play a more

radiopharmaceuticals that will take dis-

pharmaceuticals, we are committed to

important role in the development

ease screening and treatment to the

providing complete solutions for all our

of drugs by providing high quality

nextÂ level.

customersâ&#x20AC;&#x2122; needs. With major product

The key to early detection and adaptive treatment. Molecular im-

develop

We have unique expertise in the design of cyclotrons and the development, production and distribution of pharmaceutical tracers used in thousands of

applications in oncology, cardiology

data on the efficacy of the pharma-

and neurology, in PET and SPECT, in di-

ter diagnosis, patients worldwide

Growing use of radiopharmaceuticals

can benefit from safer, more effec-

The healthcare industry is using molec-

nuclear medicine solutions is one of the

tive and cheaper treatments.

ular imaging to detect diseases earlier

most complete in the industry.

ceutical under trial. Thanks to a bet-

and treat them better. Each and every day, considerable improvements are being made in diagnosis and therapy.

16 // iba MOLECULAR IMAGING

agnostics and therapy, the IBA range of

IBA’s know-how, network of research and clinical partners, versatile solutions and unique innovation capabilities allow partnering customers to redefine the standards of molecular imaging.

Brain Neurolite® Dopacis®

Thyroid CAPSION® I-131-S-1 I-131-S-2 I-123-S-1 I-123-S-2

Sentinel nodes NANOCIS

Lung PENTACIS PULMOCIS VENTIBOX VENTICIS

Liver PHYTACIS®

Bones OSTEOCIS® QUADRAMET® TECEOS® cisnaf

Cardio-vascular system ANGIOCIS® cardiogen-82® cardiolite® SERALB-125 STAMICIS® TL-201-S-1 VASCULOCIS

Kidneys NORCHOL-131 PENTACIS® RENOCIS® Filtracis

Lymphatic system NANOCIS®

Joints (various sizes) ERMM-1 RE-186-MM-1 YMM-1

Inflammation/ infection GA-67-MM-1 SCINTIMUN®

Other ELUMATIC® III FDG MIBG-131-D MIBG-131-T YTRACIS®

iba MOLECULAR IMAGING // 17

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Developing the next generation radiopharmaceuticals.

Making PET radiopharmaceuticals available worldwide IBA is the n°1 provider of PET radiopharmaceuticals worldwide. With constant innovation in our underlying production technology and an expanding global distribution network, we are helping healthcare professionals provide better patient care – safe in the knowledge that their supply of radiopharmaceuticals is predictable and reliable.

Northern America

FDG Sites Albany (NY), Cleveland (OH), Dallas (TX), gilroy (CA), haverhill (MA), kansas city (KA), los angeles (CA), Montreal (CA), Morgantown (WV), richmond (VI), romeoville (IL), somerset (OH), sterling (VA), totowa (NJ)

EUROPE GMP FDG Sites Amsterdam, bad oeynhausen, Barcelona, bern, Bordeaux, brussels, Casablanca, Coimbra, dinnington, fleurus, ghent, guilford, Lyon, madrid, Malaga, Milan, nancy, Nimes, orsay, paris AP-HP, rennes, Rome, Santander, sarcelles, Sevilla, Udine ASIA

13 GMP FDG Sites Adana, ankara, daejun, daegu, delhi, istanbul, izmir, kuala lumpur, pusan, pyeongchon, seoul(2), suncheon

18 // iba MOLECULAR IMAGING

Developing tracers that target major unmet medical needs

Molecular Imaging, a solution to build a costeffective medicine

In addition to our current portfolio, IBA

Today, society needs to put in place

is also managing a pipeline of candi-

a more cost-effective medicine. It is

product. IBA stood out as the ideal

date tracers. IBA Molecular is the only

a priority to:

partner for this critical task. Our col-

industry player that targets large scale

void the usage of drugs that are a

laboration with IBA will facilitate the

in-licensing of innovative products in

not effective on a given patient;

development and optimization of the

medical areas that are not currently

void waste by administering the a

radiochemistry and processes for

addressed, as part of its long-term

exact doses required in a given

GMP grade radiolabeling and distri-

strategy. IBA plans to launch 7 generic

patient situation;

bution of ML-10, to the standards of

or proprietary tracers between 2010 and 2015. Among those are tracers

void costly surgical procedures a where not necessary.

that are expected to answer major unmet medical needs such as ML10,

Thanks to its specificities, Molecular

an apoptosis (cellular death) trac-

imaging has the capability to facili-

er;

cancer),

tate the selection of individualized

Scintimun® (inflammation/infection) or

therapeutic plans, enable finer as-

Redectane (kidney cancer).

sessment of the response to treat-

F-Choline

(prostate

“ We looked for a partner to make APOSENSE® 18F-ML-10, our agent for PET imaging of apoptosis, a commercially available radiopharmaceutical

the most demanding end-user.” Yoram Ashery, CEO, Aposense Ltd.

More information on molecular imaging www.iba-molecular.com

ment as well as provide excellent risk assessment techniques. Molecular imaging will enable personalized diagnosis that minimizes the timing and burden of treatment to a more fragile aging population and minimizes the medical and legal risks of therapeutic plans.

iba MOLECULAR IMAGING // 19

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Delivering service and quality, every day.

IBA controls and handles all aspects of the production process, from the cyclotron itself to the distribution of 18 F-FDG through its ownÂ network IBA activities

The preparation of unit-dose 18F-FDG Injection USP, starts with bombardment of the stable target material O-Water, with an IBA cyclotron. Through a proton neutron nuclear reaction the stable 18O-Water is changed

to the 18F radioisotope, a positron emitter.

The 18F solution then enters chemical synthesis where a sugar molecule is attached to the 18F, resulting in an 18F-FDG preparation, suitable for patient Â injection.

After extensive quality control on each and every batch, the 18F-FDG is drawn into individual unit-dose syringes, assayed in the pharmacy and packaged according to official regulations.

The doses are then delivered in a timely manner to the nuclear medicine imaging department of the hospital.

Hospital activities With the advancements in PET technology, the time necessary to acquire a PET scan has dramatically decreased, while the quality of the images has significantly increased. This has resulted in both higher patient comfort during the scanning procedure as well as improved detail in the images, both leading to better study results.

FDG PET scans are often acquired in conjunction with a CT scan. The images are then fused together so the physician can easily see both the anatomical and the metabolic abnormalities in one image.

20 // iba MOLECULAR IMAGING

IBA technology: Cyclotron Solutions and Radiopharmacy design

multi-purpose capacity, the new Synthera® has been redesigned and im-

IBA is a world leader in designing and

proved so as to provide many additional benefits.

new Synthera® While keeping its main unique advantages of compactness, multi-runs and

manufacturing SPECT and PET cyclotrons and chemistry systems used to manufacture radiopharmaceuticals for nuclear medicine diagnostic procedures (molecular imaging). IBA also offers the broadest range of technologies for radioisotopes production. Up until now, IBA has provided adapted technology solutions to produce radioisotopes to hundreds of hospitals, nuclear medicine departments, PET production and distribution laboratories as well as R&D centers and biotechs worldwide. “ By working with IBA you will become an active member of the network of independent partners and experts that will shape the future of nuclear medicine. IBA innovation capabilities will be with you along the way to produce and distribute the molecules of the future.” Renaud Dehareng, President IBA Molecular

iba MOLECULAR IMAGING // 21

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. A global integrated solution for radioisotopes production. IBA supports hospitals and radio-

experience in setting up radiopharma-

“ IBA surpassed our expectations in

pharmaceutical distribution centers

ceuticals production centers. In addi-

terms of quality of equipment and

for their in-house radioisotopes produc-

tion to high-quality technology, IBA is

price. The construction and instal-

tion by providing them with a global

able to offer the support required for

lation are rigorously on time and on

solution, from project design to the

installation and maintenance, as well

budget. For sure, we will have the

operation of their facility. IBA’s custom-

as an evolutive and innovative product

most complete and modern radio-

ers can therefore concentrate on their

range with new targets for developing

pharmaceuticals production facility in

core business.

new molecules.

our country.”

IBA will, above all, support you from

IBA supports a large number of R&D

project to reality with a team of ex-

centers and biotechs worldwide by

Sérgio Chaves Cabral Project Manager, Centro Regional de Ciências Nucleares, Brazil

perts defining your needs, complying

answering their ever-growing needs

with GMP regulations, designing your

for support and original solutions for

radiopharmacy, building it on time and

research and innovative applications.

on budget, and give you the best sup-

The versatility of our product range

port during the operation.

and depth of innovations in the pipeline can provide all the tools required

When developing a radiopharmacy,

to transform an idea into a concrete

acquiring a cyclotron is only the first

saleable product.

step in a complex project. Several processes and specific equipment must be integrated into a cost effective and performing solution. For many years, IBA’s large team of experts has provided optimum support in order to achieve fully-compliant GMP centers. Through its worldwide distribution network, IBA has developed in-depth

22 // iba MOLECULAR IMAGING

More information on cyclotron solutions www.iba-cyclotronsolutions.com

Your GMP Radiopharmacy, Risk free IntegraLab® – Radioisotopes production equipment and support, from project to reality. Based on 25 years of expertise, IBA offers a global solution for your radioisotopes production. From the definition of your radiopharmaceutical production needs to the operation of your PET center, the IntegraLab® team provides full support for a cost-effective solution.

CYCLOTRONS - EXTERNAL BEAM TRANSPORT LINE - TARGETERY - CYCLOTRON CONTROL AND UTILITIES - 18F AND radiochemistry

iba MOLECULAR IMAGING // 23

IBA PARTICLE THERAPY

today, more than ever...

Cancer patients seek the most advanced and least invasive treatment possible. As a leader in particleÂ therapy, IBA continues to innovate and provide the most effective and cost efficient solutions available. Making proton therapy accessibleÂ today.

24 // iba particle therapy

iba particle therapy // 25

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Making particle therapy available to more patients everywhere, everyday. What is Particle Therapy?

attacks. Particle therapy offers the

The new frontier in cancer therapy.

most

deposition

healthy tissue in preventing side ef-

Particle therapy is a form of external

properties possible with external

fects should not be underappreciated.

beam radiotherapy using beams of

beam techniques. It also increases

The superior dose limiting properties

energetic protons, neutrons, or posi-

the effectiveness of other forms of

of protons versus x-rays are depicted

tive ions for cancer treatment. The

cancer therapy and, in clinical trials,

in the comparative distributions for

chief advantage of particle therapy

has proven easier to combine with

pediatric medulloblastoma.”

is the ability to more precisely localize

chemotherapy and surgery.

favorable

dose

the beam dosage compared to other types of external beam radiotherapy.

As a noninvasive treatment, particle

Particle therapy works by aiming en-

therapy may even be an alternative

ergetic ionizing particles at the tar-

to surgery for certain patients. Fewer,

get tumor. These particles damage

less severe treatment side effects

the DNA of tissue cells, ultimately

translate into a better quality of life

causing their death. Cancerous cells

for patients and, ultimately, health

are particularly vulnerable to such

care cost savings.

Pediatric Medulloblastoma comparison

“ The importance of dose sparing to

“Treating Patients with the NPTCC Accelerator Based Proton Treatment Facility” J. Flanz, M.D. from MGH wrote in 2003 together with T. Delaney, M.D., H. Kooy, M.D., and S. Rosenthal, M.D.

100%

Dose Deposition

60%

Photons

10%

Protons: Vital healthy organs are spared with particle therapy

26 // iba particle therapy

Making Particle therapy accessible to more patients, everyday

ing the best possible cancer treatment,

Particle therapy is an emerging cancer-

IBA is dedicated to making particle

fighting technology that is becoming

therapy available to more patients and

more widely accepted. Because there

more affordable for healthcare. IBA

are relatively few particle therapy facili-

continues to provide clinical, scientific,

ties, existing sites are treating not only

engineering and business develop-

patients from their region, but also from

ment expertise to our customers mak-

around the world. It is clear: when seek-

ing particle therapy more accessible.

patients are not deterred by distance.

Radiation therapy requires the release of many photons to damage the cancerous cells. However, the energy deposited between the skin and the tumor site and beyond limits the dose physicians can prescribe.

Proton beams deliver a precise dose of energy directly to the tumor site with what is called the Bragg peak, thereby reducing adverse effects to adjacent normal tissues inevitable with conventional radiationÂ treatment.

iba particle therapy // 27

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Where vision becomes reality.

Flexible Approach

the precise energy required to treat

Having designed and equipped the

tumors located up to 32 cm beneath

majority of the clinically operational

the skin.

particle therapy centers in the world,

The protons are directed into a fixed

IBA has unmatched experience deal-

beam treatment room  or a gantry

ing with the financial and logistical is-

treatment room  via the beam trans-

sues involved in developing a particle

port system . A rotating isocentric

therapy facility.

gantry is used to direct the beam into

IBA’s flexible approach can get a facility

the patient with sub-millimeter accu-

up and running while planning for

racy. Robotic positioning technology of-

future

fers 6 degrees of freedom allowing the

expansion.

Scalable,

multi-

room facility designs provide efficient

patient to be ideally oriented.

workflow and optimized throughput,

This system is currently the only com-

enabling

provide

mercially available technology officially

treatment and realize returns while

cleared for patient treatment in the

preparing for growth.

USA, Europe, Korea and the People’s

IBA works with leading medical equip-

Republic of China.

ment manufacturers to ensure complete

Our experience, expertise and satisfied

integration and compatibility between

users make IBA the world’s leading de-

the particle therapy system and other

veloper of Particle Therapy systems.

physicians

RESEARCH ROOM

GANTRY TREATMENT ROOMS 3

oncology systems and processes.

PROTEUS 235, a flexible configuration Inside the IBA Proteus 235 Proton Therapy system, a proton beam is generated in a 230-MeV (million electron volts) cyclotron . Protons are accelerated to

28 // iba particle therapy

Proteus 235 is the only Proton Therapy system having clearance on the 3 continents assuring quality and safety.

BEAM LINE 4

CYCLOTRON 1

FIXED BEAM TREATMENT ROOM 2

DIAGNOSTIC

iba particle therapy // 29

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Where experience really matters.

Financing Solutions

IBA. Your trusted partner

As the leader in particle therapy facil-

Any large-scale project has multiple

necessary to manage a flexible con-

ity development, IBA understands that

layers of detail, each requiring preci-

figuration design and fully integrated

financing is a critical component. And,

sion and knowledge.

facility. And we know what it takes to

with global experience, IBA also under-

That’s where experience really mat-

generate a solid business plan that

stands the various financial and busi-

ters. While others are still in the

works for a particular and unique

ness models used around the world.

design stage, IBA particle therapy fa-

situation.

For a capital-intensive project of this

cilities are at work around the world.

With leading-edge technology and

scale, gaining the leverage needed to

IBA has provided equipment, as well

unmatched experience, IBA Particle

gather the right financing program is

as clinical, scientific and engineering

Therapy can help a facility become a

paramount to success. IBA works with

expertise, to the majority of clinically

sought-after destination for the most

financial institutions such as ONDD

dedicated particle therapy centers in

advanced cancer treatment.

and the Belgian Export Credit Agency,

the world.

that understand the scope and intrica-

In addition to making particle therapy

“ At the University of Pennsylvania we

cies involved in particle therapy facility

available to more patients, IBA’s goal

took a long time going through the

development. IBA can help develop di-

is to ensure peak performance of

process and analyzing the landscape

verse, flexible programs for almost any

equipment to keep your facility on

for vendors in proton therapy. And we

financial need.

time and on budget—and ensuring

were very excited by our partnership

No matter where you’re considering

that patients get the timely and ad-

with IBA. We do believe IBA brings the

developing a particle therapy facility,

vanced treatment they need.

best technology to the table. We be-

IBA can help facilitate the all-impor-

We are helping our customers by

lieve they have the most experience in

tant financial aspects to help make

sharing our expertise and knowledge

the world with proton therapy. Based

your vision a reality. IBA will help en-

so they can make particle therapy a

on their experience, we think that they

sure particle therapy is accessible for

reality for more people. At IBA, we

are the most likely group, vendor, to

more medical professionals and their

work closely with you every step of

come through with bringing in the fa-

patients.

the way to develop the best solu-

cility on time and on budget.”

tion for your goals. We understand the commitment and experience

30 // iba particle therapy

Dr. James Metz, M.D., Radiation Oncology, University of Pennsylvania

Clinical particle therapy centers installed by IBA around the world. 2 Midwest Proton Radiotherapy Institute Bloomington, IN, USA

4 CDH Proton Therapy Center, A ProCure Center Chicago, IL, USA

ROOMS

Two gantry rooms.

2 Massachusetts General Hospital Burr Proton Therapy Center One gantry room, two inclined-beam Boston, MA, USA ROOMS

rooms, one fixed-beam room. Opening in early 2011.

ROOMS

Cyclotron, Energy Selection System (ESS), two gantry rooms.

Centre de Protonthérapie de I’Institut Curie Paris (Orsay), France New cyclotron connected to two existing fixed-beam rooms. Extension of the existing facility by one gantry room.

ProCure Proton Therapy Center Seattle, WA, USA

ROOMS

Bronowice Cyclotron Center Kraków, Poland Cyclotron, ESS, one research room, one fixed-beam room. Opening in 2012.

ROOMS

Westdeutsches Protonentherapiezentrum Essen (WPE) Essen, Germany Cyclotron, ESS, three gantry rooms, one fixed-beam room. First Proton Therapy center based on a public-private partnership (PPP) model.

In development. Expect to have four treatment rooms.

4 Federal High-Tech Medical Center

ROOMS

ProCure Proton Therapy Center in Oklahoma City Oklahoma City, OK, USA

Dimitrovgrad, Russia, Europe Cyclotron, two gantry treatment rooms, one dual beam treatment room and 1 eye treatment room. Under Construction.

ROOMS

National Cancer Center Ilsan, Korea Cyclotron, ESS, two gantry rooms, one fixed-beam room. Expandable by one gantry room.

First USA Proton Therapy facility in a private practice setting, one gantry room, two inclined-beam rooms, one fixed-beam room.

ROOMS

National Cancer Center Kashiwa, Japan Cyclotron, ESS, two gantry rooms. Developed in association with Sumitomo Heavy Industry, LTD.

5 Hampton University Proton Therapy Institute Hampton, VA, USA

ROOMS

Cyclotron, ESS, four gantry rooms, one fixed-beam room. Fastest build to date for IBA and partners.

ROOMS

4 University of Florida Proton Therapy Institute Jacksonville, FL, USA

ROOMS

Wanjie Proton Therapy Center Zibo, China Cyclotron, ESS, one gantry room, one fixed-beam room. Expandable by two additional gantry rooms. From project start to first patient treated in only three years.

Cyclotron, ESS, three gantry rooms, one fixed-beam room. Treating 100 patients per day within two years of opening.

4 ProCure Proton Therapy Center Princeton, NJ, USA

ROOMS

In development. Expect to have four treatment rooms.

ROOMS

University of Pennsylvania Health System Roberts Proton Therapy Center Philadelphia, PA, USA Cyclotron, ESS, four gantry rooms, one fixed-beam room, one research room. The largest Proton Therapy center project to date.

ROOMS

Agenzia Provinciale Per la Protonterapia (ATreP) Trento, Italy Cyclotron, ESS, two gantry rooms and one fixed-beam room. First gantry-equipped Proton Therapy center in Italy. Opening in 2013.

4 Proton Therapy Center Czech s.r.o. Prague, Czech Republic

ROOMS

Cyclotron, ESS, three gantry rooms, one fixed-beam room. The first of its kind in eastern Europe. Opening in 2012.

iba particle therapy // 31

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Proton therapy made accessible at lower costs and smaller size.

Proteus ONE™, a smaller*, more cost-effective proton therapy system

the typical gantry treatment room con-

“ The Proteus ONE™ is truly a ground-

figuration. The new design also allows

breaking system that will continue to

one-room facilities to be expanded to

revolutionize proton therapy treatment

Two of the most significant barriers to

multi-room facilities without disruption.

around the world with its reduced size

developing new proton therapy centers

Currently, gantry treatment rooms must

and cost, and greater efficiency,”

— size and cost — will soon be broken

be closed while equipment in newly

down. IBA engineers and designers

built rooms is tested, which delays

have spent more than a year devis-

treatment scheduling. The new Proteus

ing Proteus ONE™, a smaller, more

ONE™ system helps centers avoid this

cost-effective proton therapy system.

obstacle as they expand, improving

The new design also produces fewer

overall patient care. The Proteus ONE™

construction-related treatment disrup-

also offers 3-D imaging. As a patient

tions, requires less land and leaves a

lies in the new, compact gantry, a 3-D

smaller footprint. The new single-room

cone beam CT rotates around him or

system is about one-third the size of

her to capture images of the tumor

a current gantry configuration. The

prior to treatment to ensure the most

size reduction is made possible by

precise beam placement. This tumor

a much smaller cyclotron; a shorter

imaging is highly targeted, so clinicians

proton-beam route from the cyclotron

can develop a unique treatment plan for

to the treatment room; and a smaller,

each patient. While the current gantry

compact gantry. The decreased size

system has proven successful since it

directly corresponds to a significant

was introduced 11 years ago, anticipa-

cost differential. Although pricing has

tion is building for the Proteus ONE™.

not been determined at this time, the Proteus ONE™ is expected to be a much lower capital investment than

32 // iba particle therapy

* Subject to review by Competent Authorities (FDA,European Notified Bodies, et al.) before being commercially available.

Yves Jongen, IBA Founder

Proteus ONEâ&#x201E;˘, a smaller, more cost-effective proton therapy system (Subject to review by Competent Authorities (FDA,European Notified Bodies, et al.) before being commercially available)

iba particle therapy // 33

IBA DOSIMETRY

Fastest, Most Accurate, Most reliable At IBA Dosimetry we provide innovative high-end QA solutions and imaging markers for radiation diagnostics and therapy. We help healthcare professionals to improve cancer care by delivering maximum efficiency and minimized errors for better outcome.

34 // iba dosimetry

iba dosimetry // 35

about IBA // BIOASSAYS // molecular imaging // particle therapy // dosimetry // Industry Solutions //

IBA. Enabling safer radiation in medical diagnostics and treatment. What is Dosimetry?

improving the quality of cancer treat-

diagnostics (X-ray and CT imaging)

Delivering safer Radiation in Medical Diagnostics and Treatment

and in radiation therapy. Dosimetry

IBA Dosimetry offers a full range of

and industrial partners, we combine

provides the methods and solutions

innovative solutions comprising in-

expertise and knowledge in order to

that ensure the quality and effic

struments and software that enables

develop comprehensive solutions and

iency of the applied ionizing radia-

medical physicists and radiologists to

new technologies.

tion doses, helping to improve care

perform the necessary quality assur-

Innovative solutions, high quality

and patient safety.

ance and calibration procedures.

technologies and reliable relation-

More precisely, dosimetry, a sub-

When working with radiation, precision

ships with scientists and indus-

specialty of medical physics, is the

is fundamental to ensure accurate diag-

trial partners make IBA a partner of

calculation of the absorbed dose in

nosis and efficient treatment outcome

choice.

matter and tissue resulting from the

while ensuring patients’ safety. In radia-

ionizing radiation exposure.

tion therapy, health providers strive to

The radiation dose, defined by the

be 100% sure that they deliver exactly

intensity and energy, the exposure

the prescribed dose to a precisely de-

The MagicMax is a new solution de-

time, the area exposed and the

fined area in the patient’s body.

signed to make Quality Assurance

depth of energy deposition, influ-

IBA Dosimetry is the world’s N° 1 do-

in medical imaging much more effi-

ences the biological effectiveness

simetry solution provider in installed

cient for all types of X-ray diagnos-

of that dose and needs to be Qual-

systems and in bringing innovations

tic devices and procedures. Unlike

In medical fields, radiation is used in

ity Assured.

gether with our renowned scientific

One-Shot full QA solution for Medical Imaging

into hospitals. Whether in radiotherapy,